MedTrace Logo

Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus

NCT00003156 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-04-11

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent or refractory cancer of the uterus.

Conditions

  • Sarcoma

Interventions

DRUG

topotecan hydrochloride

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • David S. Miller, MD · Simmons Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-06-30
Primary Completion
2005-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003156 on ClinicalTrials.gov